Medexus Pharmaceuticals

Aptevo Therapeutics Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that focuses on the discovery, development, and commercialization of innovative therapeutics for oncology and hematology. Its marketed product, IXINITY, is a coagulation factor IX therapy indicated for patients with hemophilia B. The company's lead clinical candidate, APVO436, is a bispecific immunotherapeutic protein undergoing Phase 1/1b trials for acute myeloid leukemia and high-grade myelodysplastic syndrome. Aptevo also has several preclinical candidates, including ALG.APV-527 and APVO603, which are designed to target specific immune pathways to enhance the body’s response to cancer. These candidates are developed using the proprietary ADAPTIR platform, a modular technology that enables the creation of both monospecific and bispecific antibody therapies. Additionally, Aptevo holds a collaboration agreement with Alligator Bioscience AB for the further development of ALG.APV-527. The company was incorporated in 2016 and aims to leverage its innovative technology to improve patient outcomes in cancer treatment.

Medexus Pharmaceuticals Inc. is a specialty pharmaceutical company operating in Canada and the United States, dedicated to developing and commercializing treatments for rare and auto-immune diseases. The company's primary products include Rasuvo and Metoject, which are formulations of methotrexate for rheumatoid arthritis and other auto-immune conditions. Additionally, Medexus offers IXINITY, a therapeutic for Hemophilia B, and Rupall, indicated for various allergic conditions. The company's portfolio also features Cuvposa for sialorrhea, Gliolan for brain tumor visualization, and Treosulfan, used in stem cell transplantation preparation. Medexus Pharmaceuticals, based in Verdun, Canada, previously operated as Pediapharm Inc. and has since expanded its focus to include a range of therapeutic areas such as rheumatology, oncology, hematology, allergy, and pediatrics.

Medac Pharma specializes in the development and treatment of cancer, autoimmune diseases, and urological diseases.